Geode Capital Management Portfolio holdings
Geode Capital Management, founded in 2001 and based in Boston, Massachusetts, is a prominent institutional asset management firm known for its expertise in low-cost, systematic index investing. Originally established to manage internal index funds for Fidelity Investments, Geode became an independent entity while retaining a close relationship with Fidelity, focusing on passive investment strategies that track major market indices. The firm oversees hundreds of billions in assets, offering a range of mutual funds and separately managed accounts primarily for institutional clients, such as pension funds and endowments, with an emphasis on minimizing costs and maximizing efficiency. Geode’s disciplined, quantitative approach and avoidance of active management have made it a key player in the rise of index-based investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$524M |
| 2 |
Meta Platforms (Facebook)
META
|
+$458M |
| 3 |
Otis Worldwide
OTIS
|
+$345M |
| 4 |
T-Mobile US
TMUS
|
+$307M |
| 5 |
AbbVie
ABBV
|
+$280M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$878M |
| 2 |
RTN
Raytheon Company
RTN
|
+$537M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$435M |
| 4 |
Apple
AAPL
|
+$389M |
| 5 |
Accenture
ACN
|
+$216M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.72% |
| 2 | Healthcare | 14.52% |
| 3 | Financials | 12.98% |
| 4 | Consumer Discretionary | 10.98% |
| 5 | Communication Services | 9.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CALA
2376
DELISTED
Calithera Biosciences, Inc
CALA
| $4.66M | ﹤0.01% |
44,135
+3,750
| +9% | +$445K |
|
2377
Oric Pharmaceuticals
ORIC
$1.39B
| $4.66M | ﹤0.01% |
+138,126
| New | +$4.41M |
|
2378
Ribbon Communications
RBBN
$388M
| $4.65M | ﹤0.01% |
1,184,021
+123,212
| +12% | +$447K |
|
2379
Elbit Systems
ESLT
$39.8B
| $4.65M | ﹤0.01% |
33,918
-19
| -0.1% | -$2.57K |
|
2380
Utah Medical Products
UTMD
$230M
| $4.64M | ﹤0.01% |
52,366
+819
| +2% | +$73.5K |
|
2381
Hanmi Financial
HAFC
$960M
| $4.63M | ﹤0.01% |
476,630
+12,129
| +3% | +$119K |
|
2382
Vroom Inc
VRM
$36.7M
| $4.61M | ﹤0.01% |
+1,105
| New | +$4.29M |
|
2383
Arcutis Biotherapeutics
ARQT
$3.26B
| $4.6M | ﹤0.01% |
152,262
+91,882
| +152% | +$2.66M |
|
|
WSR
2384
DELISTED
Whitestone REIT
WSR
| $4.57M | ﹤0.01% |
629,220
+41,931
| +7% | +$267K |
|
2385
Rigel Pharmaceuticals
RIGL
$716M
| $4.57M | ﹤0.01% |
249,938
+6,580
| +3% | +$118K |
|
|
HAPN
2386
Happen Inc
HAPN
$2.41B
| $4.57M | ﹤0.01% |
1,005,013
-92,033
| -8% | -$573K |
|
2387
Byline Bancorp
BY
$1.81B
| $4.57M | ﹤0.01% |
348,682
+8,524
| +3% | +$97.6K |
|
2388
Marcus Corp
MCS
$959M
| $4.54M | ﹤0.01% |
342,520
+13,280
| +4% | +$178K |
|
|
AKCA
2389
DELISTED
Akcea Therapeutics Inc
AKCA
| $4.53M | ﹤0.01% |
330,979
+58,959
| +22% | +$910K |
|
2390
ANI Pharmaceuticals
ANIP
$1.8B
| $4.53M | ﹤0.01% |
140,132
+3,856
| +3% | +$138K |
|
2391
Cytosorbents Corp
CTSO
$23.7M
| $4.53M | ﹤0.01% |
457,757
+35,585
| +8% | +$327K |
|
2392
Haverty Furniture Companies
HVT
$455M
| $4.52M | ﹤0.01% |
282,575
-2,654
| -0.9% | -$38.7K |
|
|
AMRS
2393
DELISTED
Amyris Inc.
AMRS
| $4.52M | ﹤0.01% |
1,058,062
+311,769
| +42% | +$1.04M |
|
2394
Community Health Systems
CYH
$417M
| $4.49M | ﹤0.01% |
1,492,986
+30,925
| +2% | +$99.3K |
|
2395
Descartes Systems
DSGX
$6.63B
| $4.49M | ﹤0.01% |
85,062
+344
| +0.4% | +$15.3K |
|
|
BCOV
2396
DELISTED
Brightcove, Inc.
BCOV
| $4.48M | ﹤0.01% |
569,137
+29,168
| +5% | +$235K |
|
2397
Levi Strauss
LEVI
$9.43B
| $4.48M | ﹤0.01% |
334,463
-58,049
| -15% | -$762K |
|
|
ORBC
2398
DELISTED
ORBCOMM, Inc.
ORBC
| $4.47M | ﹤0.01% |
1,161,238
+28,444
| +3% | +$85K |
|
2399
TherapeuticsMD
TXMD
$23.6M
| $4.46M | ﹤0.01% |
71,396
+4,531
| +7% | +$264K |
|
2400
Genesco
GCO
$439M
| $4.46M | ﹤0.01% |
205,961
-1,338
| -0.6% | -$24.7K |
|
Similar funds
Geode Capital Management's Q2 2020 Portfolio in Review
As of Q2 2020, Geode Capital Management held 4,219 positions worth $467B, up 22% from $384B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Geode Capital Management's Q2 2020 filing shows 118 new, 2,550 increased, 1,055 reduced and 119 closed positions. Its largest new stake was Otis Worldwide: 6,650,358 shares worth $377M. The largest sale was Allergan plc, an estimated $878M.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 22% a quarter earlier, followed by Healthcare and Financials.
- Geode Capital Management's largest Q2 2020 buy was Otis Worldwide: 6,650,358 shares worth $377M.
- Geode Capital Management added most to Amazon in Q2 2020, an estimated $524M increase.
- Geode Capital Management's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $435M.
- Geode Capital Management fully exited Allergan plc in Q2 2020, selling an estimated $878M.
- Geode Capital Management's ten largest holdings make up 23% of its $467B portfolio in Q2 2020.
- Geode Capital Management opened 118 new positions and closed 119 in Q2 2020.
- Geode Capital Management's portfolio value rose 22% quarter-over-quarter to $467B.
Based on Geode Capital Management's 13F filing for Q2 2020, filed 13 Aug 2020.